PharmaronResults

Pharmaron 9M 2026: Orders Up 30%, CDMO +40% as Back-End Volume Accelerates

Pharmaron reported 9M 2026 revenue of RMB 12.00B (+19.0% YoY) and adjusted non-IFRS attributable net profit of RMB 1.496B (+22.0%). New orders rose over 30%, with CDMO orders up over 40% and top-20 pharma revenue up 52.5%. Q3 CDMO gross margin reached 31.1%, the clearest sign yet of back-end profitability turning up.

On November 4, Pharmaron (300759.SZ / 3759.HK) detailed its Q3 results: 9M 2026 revenue of RMB 12.00B (+19.0% YoY) and adjusted non-IFRS attributable net profit of RMB 1.496B (+22.0%). In Q3 alone, revenue was RMB 4.408B (+20.9%) and adjusted net profit RMB 587M (+24.7%), with non-IFRS net margin rising to 13.3% (+0.8 ppt QoQ). Amid a divergent CXO recovery, Pharmaron is posting both revenue and profit acceleration.

Order growth remains the headline. New orders rose over 30% in the first nine months, extending the strong momentum from H1: laboratory services orders +25%, CDMO orders +40%, and clinical research services orders +25%. Revenue from the global top-20 pharma clients reached RMB 2.720B (+52.5%), now 22.66% of total — up sharply from 32.0% growth in H1, as large-pharma order inflow accelerates.

Profitability is inflecting at the back end. Q3 CDMO revenue was RMB 1.218B (+30.1% YoY, +20.4% QoQ) with gross margin of 31.1% (+1.6 ppt YoY, +3.9 ppt QoQ) as large-scale manufacturing deliveries lifted quality of earnings. Clinical services revenue was RMB 590M (+18.0%) at 13.1% margin (+2.3 ppt YoY), the first clear margin recovery for China clinical after years of fierce competition. Laboratory services revenue was RMB 2.589B (+17.5%) at 39.1% margin (-3.4 ppt, mainly dragged by RMB appreciation).

The company maintains its full-year revenue growth guidance of 15%–20%. Capacity is the next lever: the Shaoxing campus is set to release capacity progressively from 2027, and the Lilly formulation collaboration is scheduled to land in 2028. Management noted that the small-molecule CDMO business has structural continuity, with its CRDMO pipeline serving nearly a thousand R&D projects annually, and demand for mid-to-late-stage and commercial manufacturing projects expected to stay strong.

Client mix shows the structural recovery plainly: in 9M, North America revenue +10.10%, Europe +30.07%, and mainland China +39.09%. This aligns with the sector-wide read — overseas demand stronger than domestic, and new-modality molecules stronger than traditional tracks. Capacity scarcity remains concentrated in GLP-1 peptides, ADC conjugates and oligonucleotides, while traditional mAbs and standard small molecules stay in volume competition.

China Post Securities initiated coverage with a Buy rating and a 90-day target price of RMB 57.36, forecasting 2026/27/28 revenue of RMB 16.72B / 20.03B / 24.10B. The thesis: CDMO order growth is the most visible alpha, and the Shaoxing–Lilly capacity ramp is the earnings elasticity to watch; Q4 is the key window for confirming the delivery ramp.

This article is compiled from public reporting. Original source: 中财网(2026-11-04)/ 证券之星·中邮证券研报(2026-11-03)/ 央广网(2026-11-07) · For industry reference only; not investment advice.